Mucopolysaccharidoses (MPS) — Hurler, Hunter, Sanfilippo, Morquio, Maroteaux-Lamy, Sly
Family of autosomal recessive lysosomal storage disorders (MPS II is X-linked) caused by deficiency of specific enzymes that degrade glycosaminoglycans (GAGs/mucopolysaccharides) — GAG accumulation in lysosomes throughout the body produces multi-system disease. Pediatric onset is typical; identity-affirming community within rare-disease and disability advocacy. Multi-system: skeletal dysplasia (dysostosis multiplex), short stature, joint stiffness, hepatosplenomegaly, progressive cardiac valve disease, airway obstruction (anesthesia high-risk), corneal clouding, hearing loss, cognitive impairment in CNS-involving forms. Disease-modifying ERTs: LARONIDASE (Aldurazyme, FDA April 2003) MPS I; IDURSULFASE (Elaprase, FDA July 2006) MPS II; PABINAFUSP ALFA (Izcargo) approved Japan March 2021 for neuronopathic MPS II via BBB-crossing transferrin-receptor fusion; ELOSULFASE ALFA (Vimizim, FDA February 2014) MPS IVA; GALSULFASE (Naglazyme, FDA May 2005) MPS VI; VESTRONIDASE ALFA (Mepsevii, FDA November 2017) MPS VII. MPS III (Sanfilippo) has NO approved ERT — gene therapy trials (Lysogene, Abeona, Ultragenyx UX111) are the load-bearing hope. HSCT for severe MPS I Hurler in infancy <2y is standard-of-care. Eighty-fourth deliberate non-elevation of community peptides.
What changes during this transition
The mucopolysaccharidoses (MPS) are a family of autosomal recessive lysosomal storage disorders — MPS II (Hunter) is X-linked — in which deficiency of a specific lysosomal enzyme prevents normal degradation of glycosaminoglycans. Accumulated GAGs damage tissues throughout the body: skeletal dysplasia (dysostosis multiplex), short stature, joint stiffness and contractures, hepatosplenomegaly, progressive cardiac valve disease (mitral and aortic thickening and regurgitation), airway obstruction with sleep-disordered breathing (which makes anesthesia genuinely high-risk), corneal clouding, hearing loss, coarse facies, hernias, pediatric carpal tunnel from GAG infiltration of flexor tenosynovium (NOT 'inflammation' the way the community frames it), and in CNS-involving forms progressive cognitive impairment. Diagnosis: urine GAG screen + specific enzyme activity in leukocytes/fibroblasts (diagnostic) + gene sequencing + tandem-MS heparan/dermatan sulfate biomarkers. MPS I added to US RUSP newborn screening 2016. The disease-modifying therapies are protein therapies (recombinant enzyme replacement), which a peptide-companion library names by drug. MPS I (Hurler/Hurler-Scheie/Scheie, IDUA deficiency): LARONIDASE (Aldurazyme, Sanofi/BioMarin) FDA April 2003, IV weekly. For severe Hurler in infancy <2y, HSCT is standard-of-care because it is the only intervention that crosses the BBB and preserves cognition in the severe form; ERT continued pre/peri-transplant and lifelong for somatic component. MPS II (Hunter, IDS deficiency, X-linked): IDURSULFASE (Elaprase, Takeda) FDA July 2006, IV weekly; intrathecal idursulfase-IT remains investigational. PABINAFUSP ALFA (Izcargo, Sanofi-JCR) was approved in JAPAN MARCH 2021 for neuronopathic MPS II via a BBB-crossing transferrin-receptor fusion — real multi-jurisdictional clinical evidence per Rule 11, and the Japanese approval is not contingent on FDA validation. MPS III (Sanfilippo A/B/C/D): CNS-only disease driven by heparan sulfate accumulation; progressive neurodegeneration and behavioral regression in childhood; NO APPROVED ERT (BBB barrier); the most desperate family situation in the MPS family; gene therapy programs in trials (Lysogene LYS-SAF302, Abeona ABO-102/ABO-101, Ultragenyx UX111) plus experimental intrathecal/intracerebroventricular ERTs. MPS IVA (Morquio A, GALNS deficiency): ELOSULFASE ALFA (Vimizim, BioMarin) FDA February 2014, IV weekly. MPS VI (Maroteaux-Lamy, ARSB deficiency): GALSULFASE (Naglazyme, BioMarin) FDA May 2005, IV weekly; HSCT in selected cases. MPS VII (Sly, GUSB deficiency): VESTRONIDASE ALFA (Mepsevii, Ultragenyx) FDA November 2017, IV Q2wk. Care is multidisciplinary by necessity — metabolic genetics, cardiology (valve surveillance with progressive intervention), pulmonology and ENT (upper-airway obstruction, OSA, anesthesia coordination), orthopedics (skeletal dysplasia, cervical spine instability — atlantoaxial instability in MPS IVA is real), ophthalmology, audiology, neurology, neurodevelopmental and psychiatric support, hematology if HSCT is in play, anesthesia consultation pre-procedure mandatory, and pediatric endocrinology when growth augmentation is considered. Carrier counseling for X-linked MPS II is load-bearing — mothers of affected boys, sisters, and maternal aunts may be heterozygous carriers and a subset are manifesting; pre-conception PGT options. National MPS Society (US, mpssociety.org), MPS Society UK, International MPS Network, Sanfilippo Children's Foundation, Cure Sanfilippo Foundation, and Hunter Syndrome Foundation coordinate patient advocacy internationally. Editorially: the load-bearing peptide therapies in MPS are the ERTs, pabinafusp alfa for neuronopathic MPS II in Japan, HSCT for severe MPS I Hurler in infancy, and gene therapy trials — not community-sold peptides. BPC-157, NMN, and the GH-axis stack reach MPS families through generic 'healing,' 'aging,' and 'growth' framings; none engage GAG metabolism or lysosomal storage biology. The growth-retardation overlap with the GH-axis is real (short stature is defining), and somatropin under pediatric endocrinology supervision has a legitimate place in selected cases — but community CJC-1295, ipamorelin, and tesamorelin are NOT interchangeable with somatropin, lack pediatric safety data in MPS, and stack onto an already high-risk airway and a progressive cardiac valve picture. Substrate entries exist so /ask can answer honestly when families probe; none are elevated as discovery options. Eighty-fourth deliberate non-elevation of community peptides — the pediatric population, the desperate-family dynamic, and the documented exploitation of rare-disease families by the community peptide market make the editorial posture load-bearing.
Important caveat
Mucopolysaccharidoses are managed by multidisciplinary teams: metabolic genetics + cardiology + pulmonology/ENT (airway + OSA + anesthesia high-risk) + orthopedics (skeletal dysplasia + cervical spine instability — atlantoaxial in MPS IVA) + ophthalmology + audiology + neurology + neurodevelopment/psychiatry + (HSCT cases) hematology/BMT + pediatric endocrinology when growth is in question + anesthesia consultation pre-procedure mandatory. **PEDIATRIC ONSET TYPICALLY**: editorial sensitivity load-bearing — vulnerable population + desperate families documented as targeted by community peptide markets. **AIRWAY + ANESTHESIA HIGH-RISK**: pre-op airway evaluation mandatory; failed intubation + tracheal narrowing + cervical spine instability are real. **CARDIAC VALVE DISEASE PROGRESSIVE**: serial echo surveillance; valve replacement may be required. **CERVICAL SPINE INSTABILITY MPS IVA (Morquio A)**: atlantoaxial instability + spinal cord compression risk. **DYSOSTOSIS MULTIPLEX + JOINT CONTRACTURES**: orthopedic + PT integration; pediatric carpal tunnel is GAG infiltration of flexor tenosynovium (community 'inflammation' framing wrong). **CORNEAL CLOUDING + HEARING LOSS**: ophthalmology + audiology surveillance. **COGNITIVE INVOLVEMENT (severe MPS I Hurler + neuronopathic MPS II + MPS III + MPS VII subset)**: behavioral regression in Sanfilippo (MPS III) particularly devastating + community gravity. **DISEASE-MODIFYING THERAPIES = STANDARD-OF-CARE**: **LARONIDASE (ALDURAZYME, Sanofi/BioMarin) FDA APRIL 2003** MPS I IV weekly. **IDURSULFASE (ELAPRASE, Takeda) FDA JULY 2006** MPS II IV weekly. **PABINAFUSP ALFA (IZCARGO, Sanofi-JCR) approved JAPAN MARCH 2021** for neuronopathic MPS II via BBB-crossing transferrin-receptor fusion — real multi-jurisdictional evidence; not FDA-approved (US patients seek access via trial or international travel). **ELOSULFASE ALFA (VIMIZIM, BioMarin) FDA FEB 2014** MPS IVA IV weekly. **GALSULFASE (NAGLAZYME, BioMarin) FDA MAY 2005** MPS VI IV weekly. **VESTRONIDASE ALFA (MEPSEVII, Ultragenyx) FDA NOV 2017** MPS VII IV Q2wk. **MPS III (SANFILIPPO) — NO APPROVED ERT**: most desperate family situation; gene therapy (Lysogene LYS-SAF302 + Abeona ABO-102/ABO-101 + Ultragenyx UX111) + experimental intrathecal/ICV ERTs in trials — clinical trial enrollment is the load-bearing access pathway. **HSCT FOR SEVERE MPS I HURLER INFANCY <2y**: only therapy crossing BBB preserving cognition; standard-of-care; ERT continued pre/peri-transplant + lifelong somatic component. **HSCT FOR MPS VI**: selected cases. **ANTI-DRUG ANTIBODIES**: develop in subset on ERT; clinical impact monitored. **NEWBORN SCREENING**: MPS I added to US RUSP 2016; expanding internationally. **CARRIER COUNSELING X-LINKED MPS II**: mothers + sisters + maternal aunts may be heterozygous; subset manifesting; pre-conception PGT options. **GROWTH RETARDATION RECOGNIZED**: pediatric short stature defining feature; **somatropin (recombinant human growth hormone) used in selected MPS cases under pediatric endocrinology** with stimulation-test-confirmed deficiency criteria + cardiac/airway risk weighed; **somatropin is not interchangeable with community GHRH/GHRP peptides** (different pharmacology + monitoring + pediatric safety data). **COMMUNITY PEPTIDES**: BPC-157 + NMN + GH-axis trio (CJC-1295 + ipamorelin + tesamorelin) Tier 3. **BPC-157**: 'healing peptide' framing wrong mechanism (lysosomal storage + GAG infiltration, not repair problem); pro-angiogenic VEGF concern in tissues already burdened with cardiac valve + airway obstruction; no MPS characterization. **NMN**: general-aging framing inappropriate for pediatric storage disease; no GAG engagement. **GH-AXIS TRIO**: growth retardation IS recognized in MPS — but somatropin under pediatric endocrinology is the supervised pathway; community GHRH/GHRP peptides stimulate endogenous pulsatile GH release without monitoring infrastructure + dosing precision + pediatric safety data; IGF-1 mitogenic concern in cardiac valve disease; airway risk consideration. **TESAMORELIN**: Rule 6 non-propagation — HIV-LD label doesn't extend to MPS. **ACCESS BARRIERS**: ERTs cost substantial (~$300-700k/year lifelong); pabinafusp alfa US access via trial/international travel. **PREGNANCY**: rare given pediatric onset + severity; attenuated phenotype adult patients may consider; coordinate metabolic genetics + MFM + cardiology + high-risk anesthesia consultation; X-linked transmission counseling MPS II. **TRANSITION FROM PEDIATRIC TO ADULT CARE**: increasingly relevant as attenuated phenotypes live into adulthood and post-HSCT MPS I patients reach adulthood. National MPS Society (mpssociety.org) + MPS Society UK + International MPS Network + Sanfilippo Children's Foundation + Cure Sanfilippo Foundation + Hunter Syndrome Foundation reference standards. WADA athletes (attenuated phenotype adults rare): ERT requires TUE; community GH secretagogues prohibited.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.